Vycor Medical, Inc.
VYCO
$0.20
$0.0314.29%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.44% | 22.18% | 29.50% | 47.70% | 26.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.44% | 22.18% | 29.50% | 47.70% | 26.67% |
| Cost of Revenue | 68.21% | 130.40% | 110.27% | 37.62% | 13.93% |
| Gross Profit | 27.62% | 11.91% | 19.50% | 49.29% | 28.16% |
| SG&A Expenses | 10.08% | 2.13% | 19.04% | 13.64% | 31.35% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 3.47% | 3.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.08% | 14.12% | 29.64% | 17.08% | 27.51% |
| Operating Income | 191.45% | 215.43% | -34.74% | 130.11% | -37.65% |
| Income Before Tax | 108.36% | 357.00% | -26.23% | 92.56% | -16.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 108.36% | 357.00% | -26.23% | 92.56% | -16.12% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 96.77% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 108.19% | 339.00% | -26.14% | 92.80% | -15.22% |
| EBIT | 191.45% | 215.43% | -34.74% | 130.11% | -37.65% |
| EBITDA | 347.42% | 107.52% | -45.90% | 173.88% | -88.35% |
| EPS Basic | 29.85% | 333.33% | -1.69% | 93.10% | -1.52% |
| Normalized Basic EPS | 109.09% | 350.00% | -16.67% | 94.12% | -10.00% |
| EPS Diluted | 29.85% | 300.00% | -1.69% | 93.10% | -1.52% |
| Normalized Diluted EPS | 109.09% | 300.00% | -16.67% | 94.12% | -10.00% |
| Average Basic Shares Outstanding | 1.43% | 2.28% | 2.28% | 2.29% | 0.84% |
| Average Diluted Shares Outstanding | 1.43% | 18.51% | 2.28% | 2.29% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |